Trial record 9 of 867 for:    Open Studies | "Connective Tissue Diseases"

The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2013 by Meir Medical Center
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01809574
First received: March 10, 2013
Last updated: October 6, 2013
Last verified: October 2013
  Purpose

We hypothesized that the multi-disciplinary assessment of interstitial lung disease patients would lead to a more accurate diagnosis and consequently alterations in treatment regimens that may lead to improved outcomes.


Condition
Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis
Connective Tissue Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease

Resource links provided by NLM:


Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • The number of patients with collagen related pulmonary fibrosis that are diagnosed by Rheumatologists compared to Pulmonologists. [ Time Frame: two years ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: May 2013
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

60 patients that will refer to the pulmonary outpatient or inpatients department for evaluation due to ILD will be included

Criteria

Inclusion Criteria:

  • Age above 18 years old
  • ILD according to ATS/ERS guidelines
  • Signed inform consent

Exclusion Criteria:

  • Previous lung surgery
  • Other significant systemic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01809574

Contacts
Contact: David Shitrit, Dr. 097471556 davids3@clalit.org.il

Locations
Israel
Meir Medical Center Recruiting
Kfar Saba, Israel, 972
Contact: David Shitrit, Dr    09-7471556    davids3@clalit.org.il   
Sponsors and Collaborators
Meir Medical Center
Investigators
Principal Investigator: David Shitrit, Dr Head of Pulmonary departmant, Meir Medical Center.
  More Information

No publications provided

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01809574     History of Changes
Other Study ID Numbers: 225-12-MMC
Study First Received: March 10, 2013
Last Updated: October 6, 2013
Health Authority: Israel: Ethics Commission

Keywords provided by Meir Medical Center:
Interstitial lung disease
Idiopathic pulmonary fibrosis
Connective tissue disease

Additional relevant MeSH terms:
Fibrosis
Lung Diseases
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Lung Diseases, Interstitial
Connective Tissue Diseases
Pathologic Processes
Respiratory Tract Diseases
Idiopathic Interstitial Pneumonias

ClinicalTrials.gov processed this record on September 18, 2014